Work

Psychedelic‐assisted treatment for substance use disorders: Evidence and uncertainties

Year: 2026
Type: editorial
Abstract: treatment, support and aftercare, access and eligibility, and the regulatory requirements under which services would operate.The therapeutic use of psychedelics outside formal clinical programmes raises different questions.Krawczyk et al. [9] analysed discussions in two online opioid-recovery communities and found differing views about the benefits, limitations and risks of using psychedelics to manage opioid use.In a nationally representative United States survey Priest et al. [10] estimated that 26.5% of adults who had ever used psilocybin had microdosed on their most recent occasion of use.Improving mental and physical health were prominent motivations among those who reported microdosing.These studies describe experiences, attitudes and motivations outside clinical programmes.They do not establish therapeutic benefit.Taken together, these contributions identify questions that confirmatory trials need to resolve.Among these are: do benefits persist?How are outcomes influenced by compromised masking?Do psychedelic drugs add to the psychological intervention with which they are delivered?Larger samples and longer follow-up are needed to address these questions and provide more complete reporting of potential harms.Research on delivery will also need to establish what staffing, support and aftercare these interventions require.The next stage of research should clarify both their clinical effects and the conditions under which any benefits can best be achieved.
Source: Addiction
Language: English
Field: Psychology
Open Access status: bronze
OpenAlex ID: W7236664432
Cites: 10
Cited by:
Related to: 10